Unlike some of the expressed opinions (not necessarily yours) of Australian revenue and widespread compassionate use, I find
filing with EMA and other agencies makes it much harder to screw with Anavex in the USA.
a much more realistic expression of favorable criteria as Anavex attempts to have 2-73 reviewed, MOA verified, and Revenue stream other than interest on retained fund raising.
"You can bet that all the powers-that-be will do what they can to foil Anavex."
Great post Hoskuld. You can see that clearly just by the paid company bashers here 24/7. It is actually reinforcing to see this and the desperation that goes with it.
This company has never missed on drug trial results and has proven that people get better by taking 2-73 if taken early enough in the disease.
No one is undercutting or sabotaging our trials or company. Biotech requires patience and a good understanding of clinical testing and regulatory processes. With good credible results, a safe and affordable drug will be a success. Just hang in there. Ignore silliness.